Recently, numerous advancements have been made within the realm of AML therapy, including genetically targeted therapies against FLT3, IDH1/2 and tumor protein p53 (TP53), antibody-drug conjugates, and immunotherapies. Here, IDH1 is linked to acute myeloid leukemia.